After an early surge, healthcare AI stocks sometimes find themselves in a peculiar position, which is where Tempus AI is. The company’s 2025 sales of $1.27 billion, up 83% from $693 million the year before, was quite impressive. The product roadmap has proven successful.
The strategic alliances with large pharmaceutical companies, such as Merck, Gilead, and Medtronic, which have all been announced or expanded in the last two months, demonstrate the kind of enterprise traction that healthcare AI has long promised. Nevertheless, the stock is currently selling at about $49.85, which is less than half of its top of $104.32 in October 2025. The aspect of the narrative that is worth comprehending is the disconnect.
| Tempus AI (TEM) — Key Information | Details |
|---|---|
| Company | Tempus AI, Inc. |
| Ticker | NASDAQ: TEM |
| Recent Price | Around $49.85 |
| Market Cap | Approximately $9 billion |
| 52-Week High | $104.32 |
| 52-Week Low | $41.73 |
| 2025 Revenue | $1.27 billion (up 83%) |
| 2025 Net Loss | -$245 million |
| 2026 Revenue Guidance | 25% growth |
| 2026 Adjusted EBITDA Target | $65 million |
| Next Earnings Date | May 5, 2026 |
| CEO and Founder | Eric Lefkofsky |
| Headquarters | Chicago, Illinois |
| Recent Partnerships | Merck, Gilead, Medtronic |
| Analyst Consensus | Buy, $72.83 12-month target |
The trajectory is important. As investors eagerly priced in the AI-meets-healthcare narrative, TEM surged through the summer and fall of 2025. The type of valuation that required flawless execution and ongoing sentiment expansion was established by the top near $104 in late October.
Eventually, both collapsed. The multi-quarter compression that frequently follows healthcare AI firms whenever euphoria meets the true operational reality of running a high-burn, multi-product business with significant recurring losses was the selloff that caused the stock to drop from $104 to the low $40s by April. Losses were $245 million in 2025, a 67% decrease from 2024; this was an improvement, but it was still significant for a business of this size.
Investors are aggressively divided on the present scenario going into May 5 earnings. Strong bookings and high contract value are predicted to generate 25% revenue growth and $65 million adjusted EBITDA in 2026. Oncology and data businesses are anticipated to expand by at least 30%. These are not poor figures. At this point, they’re really strong for a healthcare AI firm.
The skeptical perspective holds that the slowdown from 83% growth in 2025 to a targeted 25% growth in 2026 represents the usual realities of growing a healthcare technology company: early hypergrowth that progressively moderates as the simpler customer wins are absorbed and the harder ones have longer sales cycles. The optimistic perspective holds that the underlying business is healthier than the share price indicates and that the slowdown is cautious advice from a company that has been exceeding projections.
The optimistic thesis mostly relies on the current momentum of the partnership. In order to train AI/ML models and find precision biomarkers and resistance mechanisms, the pharmaceutical giant was granted access to Tempus’ de-identified multimodal data, Lens Platform, and Workspaces under a strategic partnership with Merck in March 2026.
Genuine enterprise validation is indicated by the extended Gilead transaction, the Medtronic ALERT trial showing quantifiable clinical impact in cardiovascular care, and the company’s increasing attendance at important medical conferences like AACR. Such high-quality healthcare AI relationships with this type of pharmaceutical counterparty are difficult to achieve and often do not disappear.
After considering all of this, the analytic community has come to a somewhat optimistic conclusion. Twelve analysts give TEM stock an average rating of “Buy,” with a 12-month stock price objective of $72.83, which is 38% higher than the most recent price. In other words, the bearish narrative around the current compression is not quite being accepted by the market.
The next few weeks will determine whether the May 5 earnings result in a beat-and-raise that reduces part of that gap or whether the stock remains range-bound due to ongoing macro uncertainties in healthcare technology.
Observing the way this stock has performed since its initial public offering (IPO), it seems likely that Tempus AI will serve as a particularly clear test case to determine whether the larger healthcare AI investment thesis truly provides operating leverage at scale.
The stock has been volatile enough that time is far more important than story, so anyone thinking about investing in TEM at current levels should size the position appropriately and speak with an experienced financial advisor. The basic narrative is true. At $50, the pricing reflects a great deal of skepticism that will need to be directly addressed on the May earnings call.
